HRP20010630B1 - 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists - Google Patents

4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists

Info

Publication number
HRP20010630B1
HRP20010630B1 HR20010630A HRP20010630A HRP20010630B1 HR P20010630 B1 HRP20010630 B1 HR P20010630B1 HR 20010630 A HR20010630 A HR 20010630A HR P20010630 A HRP20010630 A HR P20010630A HR P20010630 B1 HRP20010630 B1 HR P20010630B1
Authority
HR
Croatia
Prior art keywords
methoxy
pyridyl
heterocyclysulfonamidyl
phenoxy
preparation
Prior art date
Application number
HR20010630A
Other languages
English (en)
Croatian (hr)
Inventor
Breu Volker
Coassolo Phillippe
Neidhart Werner
Roux Sebastien
Weiss Peter
Original Assignee
Speedel Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Pharma Ag filed Critical Speedel Pharma Ag
Publication of HRP20010630A2 publication Critical patent/HRP20010630A2/hr
Publication of HRP20010630B1 publication Critical patent/HRP20010630B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HR20010630A 1999-03-03 2001-08-28 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists HRP20010630B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99104306 1999-03-03
PCT/EP2000/001660 WO2000052007A1 (en) 1999-03-03 2000-02-28 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists

Publications (2)

Publication Number Publication Date
HRP20010630A2 HRP20010630A2 (en) 2002-08-31
HRP20010630B1 true HRP20010630B1 (en) 2010-08-31

Family

ID=8237697

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010630A HRP20010630B1 (en) 1999-03-03 2001-08-28 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists

Country Status (30)

Country Link
US (2) US6417360B1 (pt)
EP (1) EP1185525B1 (pt)
JP (1) JP3488203B2 (pt)
KR (1) KR100478798B1 (pt)
CN (1) CN1342158B (pt)
AR (1) AR044720A1 (pt)
AT (1) ATE353325T1 (pt)
AU (1) AU756738B2 (pt)
BR (1) BR0008717A (pt)
CA (1) CA2364906C (pt)
CY (1) CY1108002T1 (pt)
CZ (1) CZ300324B6 (pt)
DE (1) DE60033280T2 (pt)
DK (1) DK1185525T3 (pt)
ES (1) ES2280198T3 (pt)
HK (1) HK1044943B (pt)
HR (1) HRP20010630B1 (pt)
HU (1) HUP0200080A3 (pt)
ID (1) ID30484A (pt)
IL (1) IL145051A0 (pt)
MA (1) MA26776A1 (pt)
NO (1) NO320809B1 (pt)
NZ (1) NZ513671A (pt)
PL (1) PL198815B1 (pt)
PT (1) PT1185525E (pt)
RS (1) RS50109B (pt)
RU (1) RU2201928C1 (pt)
TR (1) TR200102562T2 (pt)
WO (1) WO2000052007A1 (pt)
ZA (1) ZA200107157B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US20020184047A1 (en) * 2001-04-03 2002-12-05 Plotnick Michael A. Universal ad queue
EP1454625A1 (en) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
EP1595880A1 (en) * 2004-05-13 2005-11-16 Speedel Pharma AG Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
US20100160358A1 (en) * 2005-09-12 2010-06-24 Christoph Schumacher Pyridylsulfonamidyl-Pyrimidines for the Prevention of Blood Vessel Graft Failure
CA2641952C (en) * 2006-04-13 2011-02-01 Actelion Pharmaceuticals Ltd Treatment of early stage idiopathic pulmonary fibrosis
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
WO2010011868A2 (en) * 2008-07-23 2010-01-28 Auspex Pharmaceuticals Pyridine sulfonamide modulators of endothelin-a-receptor
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR101936054B1 (ko) 2017-06-23 2019-01-11 한국과학기술연구원 항염증 활성을 가지는 6-페녹시피리미딘 유도체, 이의 제조방법 및 이를 활성성분으로 하는 약학 조성물
TW202329952A (zh) 2021-12-17 2023-08-01 瑞士商愛杜西亞製藥有限公司 克拉生坦(clazosentan)二鈉鹽之製備方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0713875A1 (de) * 1994-11-25 1996-05-29 F. Hoffmann-La Roche AG Neue Sulfonamide
WO1996019459A1 (en) * 1994-12-20 1996-06-27 F. Hoffmann-La Roche Ag Novel sulfonamides
EP0897914A1 (en) * 1997-08-19 1999-02-24 F. Hoffmann-La Roche Ag Process for the preparation of 2,5-disubstitued pyridines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837708A (en) 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
CN1064965C (zh) * 1994-11-25 2001-04-25 弗·哈夫曼-拉罗切有限公司 新的磺酰胺类化合物及其作为药物的用途
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0713875A1 (de) * 1994-11-25 1996-05-29 F. Hoffmann-La Roche AG Neue Sulfonamide
WO1996019459A1 (en) * 1994-12-20 1996-06-27 F. Hoffmann-La Roche Ag Novel sulfonamides
EP0897914A1 (en) * 1997-08-19 1999-02-24 F. Hoffmann-La Roche Ag Process for the preparation of 2,5-disubstitued pyridines

Also Published As

Publication number Publication date
EP1185525A1 (en) 2002-03-13
CA2364906C (en) 2006-01-10
CY1108002T1 (el) 2013-09-04
IL145051A0 (en) 2002-06-30
RU2201928C1 (ru) 2003-04-10
JP3488203B2 (ja) 2004-01-19
WO2000052007A1 (en) 2000-09-08
BR0008717A (pt) 2001-12-26
HUP0200080A2 (en) 2002-06-29
KR100478798B1 (ko) 2005-03-24
HRP20010630A2 (en) 2002-08-31
AU3161100A (en) 2000-09-21
PL351794A1 (en) 2003-06-16
MA26776A1 (fr) 2004-12-20
HK1044943B (zh) 2013-03-22
AU756738B2 (en) 2003-01-23
HK1044943A1 (pt) 2002-11-08
PL198815B1 (pl) 2008-07-31
NO20014224D0 (no) 2001-08-31
DE60033280D1 (de) 2007-03-22
HUP0200080A3 (en) 2003-01-28
ZA200107157B (en) 2002-11-29
CZ300324B6 (cs) 2009-04-22
CZ20013108A3 (cs) 2002-02-13
AR044720A1 (es) 2005-10-05
YU62801A (sh) 2004-07-15
CN1342158A (zh) 2002-03-27
DK1185525T3 (da) 2007-06-04
CN1342158B (zh) 2012-06-06
ID30484A (id) 2001-12-13
US6417360B1 (en) 2002-07-09
US20020137933A1 (en) 2002-09-26
RU2001126348A (ru) 2004-03-20
ES2280198T3 (es) 2007-09-16
NZ513671A (en) 2003-04-29
EP1185525B1 (en) 2007-02-07
US6521631B2 (en) 2003-02-18
NO320809B1 (no) 2006-01-30
RS50109B (sr) 2009-03-25
DE60033280T2 (de) 2007-11-22
ATE353325T1 (de) 2007-02-15
PT1185525E (pt) 2007-05-31
CA2364906A1 (en) 2000-09-08
JP2002538156A (ja) 2002-11-12
NO20014224L (no) 2001-08-31
KR20010102480A (ko) 2001-11-15
TR200102562T2 (tr) 2002-02-21

Similar Documents

Publication Publication Date Title
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
NO986055D0 (no) Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat
KR20050085991A (en) Compounds exhibiting thrombopoietin receptor agonism
ATE203515T1 (de) Meta-substituierte phenylsulphonamidderivate
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DK0765314T3 (da) Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer
TR200102489T2 (tr) 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması
ATE260275T1 (de) Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one
DE60121461D1 (de) Kondensierte pyridoindolderivate
HRP20010630B1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
NZ513594A (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors
NZ516100A (en) Streptogramin derivatives, preparation and compositions containing them
DE69839753D1 (de) 2-(Arylphenyl)amino-imidazolin-Derivate
DE60112960D1 (de) Kondensierte pyridoindolderivate
DK0777653T3 (da) Dihydropyridinderivater som bradykininantagonister
DE69828390D1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
ATE348800T1 (de) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
MXPA03000887A (es) Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
EA200300226A1 (ru) ГЕМ-ЗАМЕЩЕННЫЕ АНТАГОНИСТЫ ИНТЕГРИНА αvβ3
BR0107405A (pt) Derivados de indol que atuam como antagonistas do receptor mcp-1
NO20033660D0 (no) HIV inhibitere N-aminoimidazolderivativer
BG106700A (en) Sodium 2-(4,6-dimethylpyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl) ethoxy-3,3-diphenylpropionate and use thereof as endothelin antagonist
YU38498A (sh) Derivati 2-(arilfenil)amino-imidazolina

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: SPEEDEL PHARMA AG, A SWISS COMPANY, CH

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120113

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20130301